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A B S T R A C T
Meningoencephalomyelitis of unknown origin (MUO) encompasses a group of idiopathic, most likely
immune mediated, inﬂammatory central nervous system diseases that cause clinical, diagnostic and
treatment challenges to veterinary neurologists. Clinical criteria for obtaining this presumptive diagnosis
are currently available, and multiple treatment protocols have previously been investigated in small
(prospective or retrospective) case series. As this group of diseases is considered fatal if left untreated, the
identiﬁcation of clinically usable prognostic indices could be of great value. This review provides an
overview of recent developments in the clinical presentation, diagnostic ﬁndings, possible prognostic
factors, treatment and outcome in dogs diagnosed with MUO.
© 2018 Elsevier Ltd. All rights reserved.
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Meningoencephalomyelitis of unknown origin (MUO) encom-
passes a group of idiopathic, non-infectious central nervous system
(CNS) diseases (Talarico and Schatzberg, 2010; Coates and Jeffery,
2014). It noteworthy that the term MUO is synonymous with MUA
(etiology) and MUE (etiology), and that all terms are intermingled
throughout the literature. This group of idiopathic non-infectious
meningoencephalomyelitides  (NIME) includes several subtypes,
including steroid responsive meningitis-arteritis (SRMA), eosinophilic
meningoencephalitis (EME), granulomatous meningoencephalomye-
litis (GME) and necrotizing encephalitis (NE; including necrotizing
meningoencephalomyelitis (NME) and necrotizing leucoencephalitis
(NLE)). As SRMA and EME have fairly distinct diagnostic character-
istics, the term MUO is introduced to cover the three speciﬁc subtypes
ofNIMEthatcanonlybeconﬁrmedbasedonhistopathology, including
GME, NME and NLE (Granger et al., 2010; Talarico and Schatzberg,
2010; Coates and Jeffery, 2014). No statistics are currently available
regarding overall incidence of MUO in the canine population, but early
reports quoted a variable incidence for GME of 5–25% of all CNS
disorders in dogs (Braund, 1985; Tipold, 1995).
Generally, a diagnosis of MUO is made based on a combination
of signalment, neurological examination results, magnetic* Corresponding author.
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1090-0233/© 2018 Elsevier Ltd. All rights reserved.resonance imaging (MRI) ﬁndings and cerebrospinal ﬂuid (CSF)
analysis (Munana and Luttgen, 1998; Adamo et al., 2007; Granger
et al., 2010; Talarico and Schatzberg, 2010; Coates and Jeffery,
2014), although these ﬁndings might vary substantially between
studies and patients (Wong et al., 2010).
This group of diseases offers both diagnostic and treatment
challenges to veterinarians. As the condition is considered fatal
without the initiation of appropriate treatment (Munana and
Luttgen, 1998; Granger et al., 2010), recent studies have evaluated
different treatment modalities and potential prognostic factors.
Etiology
The exact etiology and pathophysiology of MUO are currently
unknown and the most current theories have been discussed in a
recent literature review (Coates and Jeffery, 2014). Although MUO
most likely has a multifactorial pathogenesis, the combination of a
genetic predisposition and factors triggering an excessive immu-
nologic response are considered most important (Kipar et al.,1998;
Talarico and Schatzberg, 2010; Flegel et al., 2011; Coates and
Jeffery, 2014). Suspected triggers include environmental factors
and infectious antigens (Schatzberg et al., 2005; Greer et al., 2010;
Barber et al., 2012). This, combined with information with the
generally positive response to immunosuppressive treatment,
suggests that the conditions comprising MUO are immune-
mediated diseases (Wong et al., 2010), and the cornerstone of
medical treatment is therefore immunosuppressive therapy (Kipar
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2014).
Clinical presentation
Middle-aged toy and terrier breeds are predisposed to GME
(Munana and Luttgen, 1998; Adamo et al., 2007; Talarico and
Schatzberg, 2010), while NE predominantly affects younger toy and
small breed dogs including Pugs, Yorkshire Terriers, Maltese,
Chihuahuas, Pekingese, Papillons, Shih Tzus, Coton de Tulears and
Brussels Griffons (Talarico and Schatzberg, 2010; Cooper et al.,
2014). However, dogs of any breed and age can be affected (Granger
et al., 2010; Coates and Jeffery, 2014); a recent study revealed that
25% of dogs diagnosed with MUO were large breed dogs (>15 kg;
Cornelis et al., 2016b).
Statistical analysis of 173 GME cases, 53 MUO cases and 69 NE
cases, revealed a signiﬁcant difference in age distribution between
dogs affected with GME and NE; dogs with NE were predominantly
<4 years old, whereas the peak age for GME was 4–8 years (Granger
et al., 2010). In a series of 60 pugs with NE (Levine et al., 2008), the
median age at diagnosis was 18 months. In a series of ﬁve
Chihuahuas with NE (Higgins et al., 2008), the median age at
diagnosis was 5 years. In Pugs, fawn females are signiﬁcantly more
often diagnosed with NME compared to black males (Greer et al.,
2010). Although it is widely believed that there is a female
predominance in GME (Russo, 1979; Braund, 1985; Bailey and
Higgins, 1986; Sorjonen, 1990; Munana and Luttgen, 1998), no
statistical difference in female:male ratio has been reported in
more recent studies (Talarico and Schatzberg, 2010; Granger et al.,
2010; Cornelis et al., 2016a,b).
Historically, three histological distribution patterns are de-
scribed in dogs with GME: multifocal or disseminated, focal, and
ocular (Cuddon and Smith-Maxie, 1984; Braund, 1985; Sorjonen,
1990). Each of these distributions has been associated with a
different clinical presentation, including an acute onset and rapid
progression in dogs with multifocal GME, a more insidious or
slower progression in dogs with focal GME, and acute signs of
visual dysfunction in dogs with ocular GME (Braund, 1985;
Sorjonen, 1990; Zarfoss et al., 2006; Talarico and Schatzberg,
2009; Coates and Jeffery, 2014).
Extraneural signs are rare, but pyrexia can occasionally
accompany CNS inﬂammation (Talarico and Schatzberg, 2010).
Common laboratory tests (complete blood count, biochemistry
proﬁle, urinalysis) are often within the reference range (Thomas
and Eger, 1989; Sorjonen, 1990; Tipold, 1995).
On neurological examination, disease localization was catego-
rized as follows: a) mainly forebrain, brainstem or multifocal for
GME; b) focal (forebrain, brainstem) or multifocal in MUO; or c)
mainly forebrain in cases with NE (Granger et al., 2010; Talarico
and Schatzberg, 2010; Coates and Jeffery, 2014; Cornelis et al.,
2016a). Large breed dogs presented signiﬁcantly more often with
identiﬁable decreased mentation compared to small breed dogs
(Cornelis et al., 2016b). Eight percent of dogs diagnosed with GME
presented with neurological deﬁcits suggestive of a myelopathy
(Granger et al., 2010). The myelopathy could be localised anywhere
in the spinal cord, and there were clinical sings ranging from
general proprioceptive ataxia to paresis or plegia; spinal hyperes-
thesia was a common ﬁnding (Grifﬁn et al., 2008; Wong et al.,
2010; Cornelis et al., 2017a).
Diagnostic ﬁndings
As previously stated, MUO is a clinical diagnosis that can be
achieved based on a combination of signalment, neurological
examination results, cross-sectional intracranial imaging abnormal-
itiesandCSFanalysis (Munanaand Luttgen,1998;Adamo etal., 2007;Talarico and Schatzberg, 2010; Coates and Jeffery, 2014). Granger
et al. (2010) systematically reviewed 457 published cases with NIME
(including MUO, GME and NE) and formulated guidelines to recruit
cases diagnosed with MUO in the absence of a histopathological
diagnosis. The following four inclusion criteria have been estab-
lished: (1) dogs older than 6 months of age; (2) multiple, single or
diffuse intra-axial hyperintensities on T2-weighted (T2W) MR
images; (3) pleocytosis on CSF analysis with >50% of monocytes/
lymphocytes; and (4) rule out of infectious diseases commonly
occurring in the speciﬁc geographic area (Granger et al., 2010). As
stated previously, a deﬁnitive diagnosis can only be obtained by
histopathological examination (Uchida et al., 2016).
Cross-sectional imaging
MRI has been reported to be 94.4% sensitive and 95.5% speciﬁc
for detecting a brain abnormality, with similarly high performance
for classifying neoplastic and inﬂammatory disease. In contrast,
MRI is only 38.9% sensitive for classifying cerebrovascular disease
(Wolff et al., 2012). It is also important to note that up to 7% of dogs
in one study (2/25 dogs, one diagnosed with GME and one with
MUO) showed no abnormalities on T2W MR images (Talarico and
Schatzberg, 2010; Granger et al., 2010), which may cause similar
cases not to be included in pro – or retrospective studies if no
histopathology is available. Equally for CT imaging, up to 14% (5/36
dogs, speciﬁc diagnosis not speciﬁed) from studies revealed no
abnormalities (Granger et al., 2010). Overall, the sensitivity of
imaging in identifying all inﬂammatory abnormalities suspected
from the neurological examination remains quite low (<60%;
Granger et al., 2010). Additionally, MRI abnormalities were only
observed in 76% of cases with inﬂammatory CSF ﬁndings in one
study (19/25 dogs; Lamb et al., 2005). Although the use of cross-
sectional imaging might aid in differentiating between the
different types of idiopathic meningoencephalitides (Talarico
and Schatzberg, 2010), no information is currently available
regarding the use of MRI to differentiate between histopathologi-
cally conﬁrmed cases of GME, NME and NLE.
One study speciﬁcally focused on the MRI ﬁndings in 11 dogs
with histopathologically conﬁrmed GME (Cherubini et al., 2006).
The focal, multifocal or diffuse T2W and ﬂuid attenuating inversion
recovery (FLAIR) hyperintensities were located in the forebrain,
brainstem or cerebellum (Fig. 1). Abnormalities were scattered
throughout grey and white matter, showed variable intensity on
T1-weighted (T1W) images, and variable degrees of contrast
enhancement. Imaging ﬁndings suggestive of vasogenic oedema in
the white matter were commonly present on T2W images, where
meningeal enhancement was not commonly apparent and
minimal if present (Cherubini et al., 2006; Talarico and Schatzberg,
2010; Coates and Jeffery, 2014). The distribution of abnormalities
on MR imaging (location in grey or white matter) was consistent
with the histopathological ﬁndings (Cherubini et al., 2006).
The most common MRI abnormalities reported in dogs with
NME are asymmetrical, multifocal and located in the forebrain
(more severe lesions in parietal and occipital lobes have been
described); are hyperintense on T2W and FLAIR images; and
typically affect the cortical grey and subcortical white matter with
loss of grey/white matter demarcation and variable degrees of
contrast enhancement of the parenchymal lesions on T1W post-
contrast images (Flegel et al., 2008; Young et al., 2009; Talarico and
Schatzberg, 2010; Fig. 2). However, cerebellar and brainstem
lesions were also detected in 4/18 and 3/18 cases in one study,
respectively (Young et al., 2009). Meningeal enhancement can also
be present, accompanied by mass effect and varying degrees of
ventriculomegaly (Coates and Jeffery, 2014).
In NLE, multiple asymmetrical cerebral white matter and
brainstem abnormalities have been detected (von Praun et al.,
2006). These abnormalities were typically hyperintense on T2W
Fig. 2. Sagittal (A) and transverse (B) T2W and transverse FLAIR image (C) at the level of the interthalamic adhesion in a 2-year-old female entire Maltese terrier with a
histopathological diagnosis of NME. Note the diffuse forebrain hyperintensity affecting the cortical grey and subcortical white matter on the T2W and FLAIR images, involving
the frontal, temporal and parietal lobes. Mass effect causing loss of cerebral sulci and occlusion of the right lateral ventricle can be observed. The deep cerebral grey matter,
brainstem and cerebellum seem unaffected in the presented case (Images courtesy of The Royal Veterinary College, University of London).
Fig. 1. Sagittal (A) and transverse (B) T2W and transverse FLAIR image (C) at the level of the interthalamic adhesion in a 6-year-old female entire Golden retriever with a
histopathological diagnosis of GME. Note the diffuse hyperintensities on the T2W and FLAIR images affecting grey (both cortical and deep grey matter) and white matter
involving forebrain (temporal lobe) and brainstem (Images courtesy of The Royal Veterinary College, University of London).
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necrosis. Contrast enhancement of parenchymal abnormalities
was minimal in two reported studies (Talarico and Schatzberg,
2010; Coates and Jeffery, 2014). There was lack of meningeal
enhancement and mass effect, with varying degrees of ventricu-
lomegaly in a third study (Coates and Jeffery, 2014; Fig. 3).
Fifty-seven dogs with meningomyelitis of unknown origin have
been reported, including three dogs with histopathologically
conﬁrmed GME (Cherubini et al., 2006; Grifﬁn et al., 2008; Wong
et al., 2010; Cornelis et al., 2017a). Imaging ﬁndingswere available for
36 of the 57 cases, using different types of imaging modalities.
Twelve dogs underwent myelography alone or computed tomogra-
phy (CT) -myelography; there were no abnormalities in 11 dogs and a
ventral extradural spinal cord compression in one dog (Wong et al.,
2010). MRI was performed in 25 dogs, revealing no abnormalities in
three dogs, multifocal poorly demarcated intramedullary T2W
hyperintensities withvariablecontrastenhancement insix dogs, and
a focal ill-deﬁned, intramedullary T2W hyperintense and T1W
isointense abnormalities with variable contrast enhancement of the
parenchymal lesionand/oroverlying meninges in16 dogs (Cherubini
et al., 2006; Wong et al., 2010; Cornelis et al., 2017a).
Other imaging modalities, including positron emission tomog-
raphy (PET) in NME, ﬂuorodeoxyglucose PET (FDG-PET) and single
voxel proton magnetic resonance spectroscopy (1H MRS) in MUO,
and transcranial sonographic ﬁndings in GME, were investigated as
diagnostic modalities (Eom et al., 2008; Kang et al., 2010; Carvalho
et al., 2012; Carrera et al., 2016). However, further studies with
larger sample sizes are necessary to evaluate the clinical usefulness
of these imaging modalities.
Cerebrospinal ﬂuid analysis
Cerebrospinal ﬂuid pleocytosis, deﬁned as an increase in total
nucleated cell count (TNCC; reference <5 white blood cells (WBC)/Fig. 3. Sagittal (A) and transverse (B) T2W and transverse FLAIR image (C) at the level of
histopathological diagnosis of NLE. Note the multiple hyperintensities mainly affecting th
forebrain white matter (Images courtesy of The Royal Veterinary College, University ofmL), is one of the proposed diagnostic criteria for MUO (Granger
et al., 2010). However, the prevalence of CSF cytological
abnormalities varies greatly across the literature, possibly due to
major differences in methodology and inclusion criteria applied.
Additionally, CSF cytology can be normal in 3–57% of dogs with
MUO (Menaut et al., 2008; Granger et al., 2010), which is
comparable to the results of a study in dogs with GME and NE,
where CSF analysis revealed normal cell counts in 16% dogs with
GME and 12.5% dogs with NE (Granger et al., 2010). Albumino-
cytological dissociation can occur in cases with a normal cell
counts and increased CSF protein concentrations (Tipold, 1995;
Granger et al., 2010). Lymphocytes were the predominant cell type
in 42% of GME cases and 71% of MUO cases, whereas monocytes
and lymphocytes were found equally in NE; neutrophils were the
predominant cell type in <10% of cases in each group (Granger
et al., 2010). In summary, most cases had a CSF mononuclear
pleocytosis and as such a pleocytosis with >50% mononuclear cells
has been proposed as a diagnostic criterion for dogs with MUO
(Smith et al., 2009; Granger et al., 2010; Lowrie et al., 2013; Coates
and Jeffery, 2014). However, dogs with MRI abnormalities
suggesting increased intracranial pressure but where CSF collec-
tion is not performed are therefore often excluded from CSF
studies, creating a possible bias towards less severe cases (Cornelis
et al. 2016a).
Of the 51 reported dogs with meningomyelitis of unknown
origin, CSF ﬁndings were only available for 22 dogs (Cherubini
et al., 2006; Grifﬁn et al., 2008; Cornelis et al., 2017a). Although
pleocytosis was seen in all dogs, no deﬁnitive conclusions can be
drawn as the presence of inﬂammatory CSF was used as an
inclusion criterion in 21 of those dogs (Cornelis et al., 2017a). Total
protein measurement was performed in 19 dogs, revealing
increased total protein concentration in 17 dogs (ranging from
31–1630 mg/dL; Cherubini et al., 2006; Cornelis et al., 2017a). the interthalamic adhesion in a 4-year-old male neutered Labrador retriever with a
e cerebral white matter and the brainstem. Cystic areas were present throughout the
 London).
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Both stereotactic CT-guided brain biopsy procedures (Koblik
et al., 1999) and free-hand biopsies through a mini-burr hole
(Flegel et al., 2012) have been described in dogs with inﬂammatory
CNS disease, but these are not easily clinically applicable.
Diagnostic accuracy ranged from 82% (n = 17; Flegel et al., 2012)
to 100% (n = 3; Koblik et al., 1999), although results should be
interpreted with caution due to the relative small sample sizes.
None of the dogs died during the procedure. Complications
occurred in 12–29% of dogs, including transient epistaxis, transient
exacerbation of neurological signs, obtundation progressing to
coma, medically uncontrollable seizures, tetraparesis, hemipare-
sis, ataxia and loss of conscious proprioception (Koblik et al., 1999;
Flegel et al., 2012). Most of these signs resolved within 3–14 days
(Flegel et al., 2012).
Treatment
Although the ideal for a clinical trial is a randomized, placebo-
controlled, double-blinded, prospective study, it is generally
accepted that use of a placebo control treatment group is unethical
because dogs with MUO have a poor outcome without treatment
(Coates et al., 2007; Smith et al., 2009; Coates and Jeffery, 2014).
Historically, different inclusion criteria have been used, and
because in some studies immune mediated medication was only
initiated after results of infectious disease testing were known,
resulting in a delay in treatment results, responses and outcomes
are difﬁcult to compare (Adamo et al., 2007; Coates et al., 2007;
Wong et al., 2010). Additionally, dogs that die within hours of
diagnosis (with or without immunosuppressive therapy) are
sometimes excluded from enrolment or from further analysis,
which inevitably results in improved survival times (Lowrie et al.,
2013; Cornelis et al., 2016a; Lowrie et al., 2016). Alternatively, dogs
that are treated based on clinical suspicion (lacking a full
diagnostic work-up), will also not fulﬁl the inclusion criteria of
most studies, therefore possibly underestimating survival time.
Additionally, it is worthwhile mentioning that anesthesia and CSF
collection can be associated with side effects, possibly affecting
outcome in cases with a complete diagnostic work-up.
As previously stated, the exact etiology and pathophysiology of
MUO remains unknown, but the cornerstone treatment modality is
generally agreed to be immunosuppressive therapy. Several
treatment protocols using different inclusion criteria resulting in
different long-term survival times have been reported as a result
(Sisson et al. 1989; Gregory et al., 1998; Munana and Luttgen, 1998;
Adamo and O’Brien, 2004; Gnirs, 2006; Zarfoss et al., 2006; AdamoTable 1
A summary of the most commonly used treatment options in dogs with meningoence
Drug Number
of dogs
included
Dose Side effects 
Only
prednisolone
116 0.5–30 mg/kg/
day
Polyuria, polydipsia, panting, muscle weak
changes, predisposition to infections, mus
resistance, hyperglycemia, vacuolar hepat
hypercoagulability
Cytosine
arabinoside
158 CRI: 100–
300 mg/m2
over 8–24 h
SC: 4 SC
injections of
50 mg/m2 in
48 h
Myelosuppression, gastro-intestinal upset
treatment lethargy, dysphagia or limb tre
skin changes (increased shedding or alope
dermatitis; transient to intermittent pelvi
inﬁltrative lung disease; anterior uveitis; 
deep pyoderma at the injection site
Ciclosoporine 26 3–15 mg/kg
PO every 12 h
Hypertrichosis; transient lymphopenia; v
gastro-intestinal adverse effects with life-et al., 2007; Coates et al., 2007; de Stefani et al., 2007; Feliu-Pascual
et al., 2007; Uriarte et al., 2007; Jung et al., 2007; Menaut et al.,
2008; Pakozdy et al., 2009; Smith et al., 2009; Granger et al., 2010;
Kang et al., 2010; Wong et al., 2010; Flegel et al., 2011; Jung et al.,
2011; Jung et al., 2013; Lowrie et al., 2013; Beckmann et al., 2015;
Mercier and Barnes Heller, 2015; Barnoon et al., 2016; Cornelis
et al., 2016a; Lowrie et al., 2016; Cornelis et al., 2017b).
Overall, treatment effect is monitored by clinical response and
resolution of neurologic deﬁcits, and occasionally by repeated CSF
analysis and MR imaging (Coates and Jeffrey, 2014). In a small
cohort of dogs, Lowrie et al. (2013) suggested that a combination of
MR imaging and CSF analysis provided greater sensitivity for
prediction of relapse than one modality alone. However, repeating
those examinations might be difﬁcult to justify because of the risks
associated with anesthesia and CSF collection.
Glucocorticoids such as prednisolone remain the mainstay of
treatment initially and in the longer term, are mostly combined
with other immunosuppressive drugs as cytosine arabinoside or
ciclosporine. A summary of these treatment options can be found
in Table 1.
Other immunosuppressive agents
Other immunosuppressive agents have been described in
combination with prednisolone for treatment of MUO, including
azathioprine (Wong et al., 2010), procarbazine (Cuddon, 2002;
Coates et al., 2007), lomustine (Uriarte et al., 2007; Flegel et al.,
2011), vincristine and cyclophosphamide (Smith et al., 2009),
leﬂunomide (Gregory et al., 1998), and mycophenolate mofetil
(Feliu-Pascual et al., 2007; Barnoon et al., 2016).
The following side effects were described in those studies:
myelosuppression (19%) and hemorrhagic enteritis (15%) with
procarbazine (Coates et al., 2007); leukopenia, severe thrombocy-
topenia and hemorrhagic gastro-enteritis with lomustine (Flegel
et al., 2011); myelosuppression, hemorrhagic cystitis and pyometra
with vincristine and cyclophosphamide (Smith et al., 2009); and
hemorrhagic diarrhoea within the ﬁrst 2 weeks of treatment with
mycophenolate mofetil (Feliu-Pascual et al., 2007; Barnoon et al.,
2016). The side effects encountered with the combination of
vincristine and cyclophosphamide were unacceptable to the
authors, who excluded this protocol from further investigation
(Smith et al., 2009). On treatment with azathioprine (n = 40), major
adverse events were infrequent but included poor coat or thin skin
(13/40), urinary tract infection (3/40), vomiting (3/40), corneal
ulcers (2/40), diabetes mellitus (2/40), renal failure, keratocon-
junctivitis sicca, cruciate ligament rupture, hepatic mass, mam-
mary gland adenoma, lymphoma, demodectic mange and septicphalomyelitis of unknown origin (MUO).
Median
survival
References
ness, dermatological
cle atrophy, insulin
opathy, and
28–
602 days
Coates et al., 2007; Pakozdy et al., 2009;
Granger et al., 2010; Flegel et al., 2011; Mercier
and Barnes Heller, 2015; Cornelis et al., 2017b
, transient post-
mors; mild coat and
cia, mild localized
c limb weakness;
calcinosis cutis and
26–
1063 days
Cuddon, 2002; Zarfoss et al., 2006; de Stefani
et al., 2007; Menaut et al., 2008; Smith et al.,
2009; Lowrie et al., 2013; Lowrie et al., 2016
omiting; severe
threatening anemia
236–
930 days
Adamo and O’Brien, 2004; Gnirs, 2006; Adamo
et al., 2007; Jung et al., 2007; Pakozdy et al.,
2009; Kang et al., 2010; Jung et al., 2013
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including weight gain, poor coat, hypertriglyceridemia, thrombo-
cytosis, and elevated liver enzyme activities, could have been
associated with concurrent administration of glucocorticoids
(Wong et al., 2010).
Median survival times (MSTs) were available for some studies
and are as follows: 425 days for procarbazine (Coates et al., 2007),
150–740 days for lomustine (Uriarte et al., 2007; Flegel et al., 2011),
198 days for vincristine and cyclophosphamide (Smith et al., 2009),
250 days for mycophenolate mofetil (Barnoon et al., 2016), and
1834 days for azathioprine (Wong et al., 2010).
Radiation therapy
Three studies comprising 17 dogs examined the additional
effects of radiation therapy (Sisson et al., 1989; Munana and
Luttgen, 1998; Beckmann et al., 2015). This resulted in MSTs of
404–476 days, without any early or late radiotherapy reactions
(Munana and Luttgen, 1998; Beckmann et al., 2015).
Prognostic factors
As MUO is generally considered a fatal disease (Munana and
Luttgen, 1998), multiple studies have attempted to identify
prognostic factors for dogs diagnosed with MUO. Unfortunately,
as most studies have included relatively small numbers of dogs
receiving different treatment regimens, conﬂicting results have
been reported, making the majority of ﬁndings difﬁcult to apply in
a clinical setting.
Younger age at time of diagnosis was signiﬁcantly associated
with improved survival in 52 dogs with MUO (Oliphant et al.,
2017). In 42 dogs with GME, Munana and Luttgen (1998) reported
signiﬁcantly longer STs with focal (21 dogs) vs. multifocal (21 dogs)
neurological signs. Additionally, dogs with focal forebrain signs
had a signiﬁcantly longer STs compared to dogs with focal signs
related to other areas of the CNS. Dogs with focal forebrain signs
that underwent radiation therapy had a signiﬁcantly longer ST
compared to dogs with focal forebrain signs that did not undergo
radiation therapy (Munana and Luttgen, 1998). The ﬁnding of
increased survival for dogs with focal neurological signs was,
however, not repeated in more recent studies, including a total of
187 dogs with MUO (Coates et al., 2007; Lowrie et al., 2013;
Cornelis et al., 2016a). Dogs presenting speciﬁcally with seizures or
altered mentation had signiﬁcantly shorter STs (Bateman and
Parent, 1999; Coates et al., 2007; Granger et al., 2010) and a
signiﬁcantly higher risk of dying within the ﬁrst week after
diagnosis (Cornelis et al., 2016a). A signiﬁcantly longer MST was
recorded in 25 dogs that were presented within 7 days of onset of
clinical signs, compared to those presented after more than 7 days,
suggesting that early diagnosis and treatment might inﬂuence
survival time (Barnoon et al., 2016).
One study identiﬁed a lower CSF TNCC as signiﬁcantly
associated with improved survival in 52 dogs with MUO (Oliphant
et al., 2017), while others found that neither CSF TNCC nor protein
concentration had an effect on survival time in 148 dogs with MUO
(Coates et al., 2007; Cornelis et al., 2016a). The study by Lowrie
et al. (2013) failed to demonstrate an association between normal
CSF analysis and improved outcome, but did ﬁnd an association
between abnormal CSF analysis and relapse or poor outcome in 39
dogs with MUO (Lowrie et al., 2013). In the study by Mercier and
Barnes Heller (2015), CSF analysis was repeated 1 month after
diagnosis in 16 dogs with MUO, and results suggested that serial
CSF analysis might be a valid tool for monitoring success or failure
of treatment in dogs diagnosed with MUO and treated with
glucocorticoid monotherapy. It should be noted that CSF analysis
always carries a risk of complications, including neurologic
deterioration and/or death, and the clinician should always weighany beneﬁts against potential risks. Additionally, repeat CSF
analysis is performed under general anesthesia and can be cost-
prohibitive.
Various ﬁndings on MR imaging have been evaluated for their
possible prognostic value, but to date midline brain shift in 52 dogs
with MUO (Oliphant et al., 2017), contrast enhancement on T1W
images, and lesion burden in 18 Pug dogs with NME (Young et al.,
2009), and the presence of focal, multifocal or diffuse abnormali-
ties, including anatomical localisation, mass effect, brain hernia-
tion, parenchymal and meningeal contrast enhancement in 116
dogs with MUO (Cornelis et al., 2016a) were not associated with
survival. However, mass effect, loss of identiﬁable cerebral sulci
and foramen magnum herniation were all signiﬁcantly associated
with increased risk of mortality in dogs with MUO, but the
association with prognosis was poor for these ﬁndings and none
were predictive of long-term outcome (Lowrie et al., 2013; Lowrie
et al., 2016). Resolution of MRI abnormalities 3 months after
diagnosis was associated with a good outcome in 39 dogs with
MUO (Lowrie et al., 2013).
In one study, relapse was recorded in 65% of 39 dogs within a
median of 210 days after diagnosis (Lowrie et al., 2013). This study
revealed that abnormal CSF analysis at 3 months was associated
with higher risk of relapse, but the combination of MRI and CSF
analysis provided greater sensitivity for predicting relapse than
one modality alone. Discontinuation of treatment before resolu-
tion of MRI abnormalities always resulted in relapse (Lowrie et al.,
2013).
Outcome
Published studies suggest that 15% of dogs with GME die before
being treated (Munana and Luttgen, 1998; Granger et al., 2010).
Despite the initiation of appropriate and aggressive immunosup-
pressive treatment, 56% of dogs in one study died or were
euthanased because of MUO, and 33% of these dogs did so within
3 days after diagnosis (Lowrie et al., 2013). Cornelis et al. (2016a)
reported similar results; 25% of dogs in a study of 116 dogs died or
were euthanased within 7 days after diagnosis, despite initiation of
appropriate treatment. Levine et al. (2008) reported that dogs with
NME that had received any form of treatment had a signiﬁcantly
longer mean ST than those that received no treatment. Most dogs
with MUO or GME that die, do so within the ﬁrst 3 months after
diagnosis (Thomas and Eger, 1989; Smith et al., 2009; Lowrie et al.,
2013). Eighteen of nineteen dogs (95%) survived for 1 month in one
study (Smith et al., 2009), but only one of those dogs failed to
survive for 1 year. Additionally, dogs that survived for 1 year often
lived for a relatively long period beyond this, suggesting that
animals alive after 1 month might have a relatively good chance of
living several more years (Smith et al., 2009).
In the published literature, 57 dogs with MUO have been
described and follow-up information was available for 50 dogs.
Overall, 30/50 dogs (60%) died or were euthanased because of their
disease, and 18 dogs were alive at time of data capture (Grifﬁn
et al., 2008; Wong et al., 2010; Cornelis et al., 2017a). Spontaneous
death in cases diagnosed with meningomyelitis of unknown origin
might have been caused by progression of the disease with
involvement of the brain, although further studies are needed to
conﬁrm these ﬁndings.
Closing remarks
MUO is a disease entity that is characterised by variable
pathologies, and many questions remain about its pathogenesis,
diagnostic criteria, the most appropriate treatment protocol, short
and long-term prognosis and outcome. From a clinical point of
view, performing all diagnostic tests to reach a (more certain)
I. Cornelis et al. / The Veterinary Journal 244 (2019) 37–44 43diagnosis may be cost prohibitive, could result in neurologic
deterioration and even possibly delay appropriate treatment.
Additionally, brain biopsy to obtain a deﬁnitive diagnosis is limited
in availability and is associated with signiﬁcant risk of adverse
outcome. Why do some animals survive for years with or without
therapy in a disease that is considered often fatal? Was the initial
diagnosis inaccurate? What is the best treatment option, if this
exists? What is the best way to evaluate the effect of therapy? Is it
better to evaluate treatment outcome by clinical improvement or
by means of further quantitative investigations? Does repeat CSF
sampling and/or MRI give an accurate reﬂection of therapeutic
success and is the beneﬁt of repeated anesthesia and CSF collection
worth the risk of collection? Different inclusion criteria make
interpretation of and comparisons between previous studies
difﬁcult and consideration should be given to revisiting the strict
diagnostic criteria used. This might enable multicentre clinical
studies to further characterise the clinical presentation, diagnostic
ﬁndings, treatment outcome and prognosis in dogs with presumed
MUO, by accepting the possibility that not all dogs will have met all
the inclusion criteria in previous studies. Further investigation of
genetic factors and possible triggers should also be undertaken.
Conclusion
As a histologic diagnosis is not generally available ante mortem,
the clinician should rely on previously established clinical diagnostic
criteria used for the diagnosis of MUO. MUO is the most common
cause of meningoencephalitis in dogs in countries where canine
distemper virus infection is rare and it is generally considered to
mainly affect young to middle aged, medium to small breed toy and
terrier breed dogs. However, the results of recent studies indicate
that dogs of all breeds and all ages can be affected. MRI is considered
the imaging modality of choice for the diagnosis of intracranial or
spinal cord abnormalities that are consistent with inﬂammatory CNS
disease. Criteria for differentiating different pathologic forms of
MUO (GME, NME and NLE) have not been determined on the basis of
MRI ﬁndings, and the importance of this distinction clinically or with
respect to pathogenesis, treatment and outcome has not been
determined. Immunosuppressive drugs are recognized as the main
treatment for MUO. Several studies have reported on long-term
outcome in MUO, and reported MSTs range from 28–1834 days. Two
studies suggested that 25–33% of dogs will die within 1 week after
diagnosis, despite the initiation of appropriate treatment. It is
currently unclear why some dogs respond favourably to treatment,
while others do not, despite appropriate treatment. Further studies
are necessary to explore the underlying etiology and pathophysiol-
ogy of MUO, to identify diagnostic indicators that may standardize
clinical diagnosis, to develop evidence-based treatment protocols,
and to identify clinically reliable prognostic indicators.
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